Navigation Links
Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
Date:9/14/2010

Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its... -- JERUSALEM, September 14, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries, FDA Approval Click to view news release full screen  

Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule

   

Proof of Concept Study for a New Indication of Oral Insulin Capsule for Type 1 Diabetics

JERUSALEM, September 14, 2010 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) announced today successful results in an exploratory clinical trial testing the effectiveness of its oral insulin capsule (ORMD-0801) in Type I diabetes patients suffering from uncontrolled diabetes.

In parallel to Oramed's main focus in developing an oral insulin capsule for management of Type II diabetes the company is exploring an application of its oral insulin capsule toward cases of uncontrolled Type I diabetics. Unstable or labile diabetes is characterized by recurrent, unpredictable and dramatic blood glucose swings often linked with irregular hyperglycemia and sometimes serious hypoglycemia affecting Type I diabetes patients. This newly completed exploratory study was a proof of concept study for defining a novel indication for ORMD-0801. The encouraging results justify further clinical development of ORMD-0801 capsule application toward management of uncontrolled diabetes.

"This study marks an impressive milestone for Oramed," says Nadav Kidron, CEO of Oramed Pharmaceuticals. "These results suggest a possible novel and unique indication for our oral insulin product in the treatment of Type I diabetes in addition to our main indication for Type II diabetes."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com.

Safe Harbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts: Oramed Pharmaceuticals Inc. Tara Horn Office: +1-646-240-4193 Cell: +972-54-334-4318 Email: tara@oramed.com
'/>"/>

SOURCE Oramed Pharmaceticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
2. Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
3. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
4. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
5. Oramed Pharmaceuticals Announces Filing of Two Registration Statements
6. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
7. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
8. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
9. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
10. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
11. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017  The Pharmaceutical Care ... Senate Finance Committee,s vote to advance the nomination of ... Medicare and Medicaid Services Administrator: "The ... bright spot in American health care. By offering an ... using cutting-edge, cost-saving tools like pharmacy networks and home ...
(Date:3/1/2017)... , March 1, 2017 The global  Intraoperative Neuromonitoring (IONM) ... new report by Grand View Research, Inc. The intraoperative neuromonitoring market is anticipated ... the hospitals adopting intraoperative monitoring in a wide spectrum of surgeries. ... ... Grand View Research Logo ...
(Date:2/28/2017)... Mechanical Ventilators Market: Scope of the Study ... This report provides forecast and analysis of the mechanical ... provides historical data of 2015 along with forecast from ... and volume (units). The report also includes macroeconomic indicators ... It includes drivers and restraints of the mechanical ventilators ...
Breaking Medicine Technology:
(Date:3/1/2017)... BEVERLY HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... invasive cryoablation for the treatment of early stage breast cancer and where it fits ... Screens, Genes & The Choices We Make .” The event brings together leading cancer ...
(Date:3/1/2017)... ... March 01, 2017 , ... Expert on international living ... mobile app Time & Go. , Time & Go app is the ultimate strategic ... and well-being. Efficient time management methods enable people to work smarter, not harder, that's ...
(Date:3/1/2017)... , ... March 01, 2017 , ... March 2017 – ... months when people don’t want to stop training to brave the cold weather, snow ... treadmill to a small incline can help protect these vulnerable joints, says orthopaedic surgeon ...
(Date:3/1/2017)... ... March 01, 2017 , ... “McFarnia”: a suspenseful tale ... the truth about his life and mysterious disappearance. “McFarnia” is the creation of published ... in North Carolina. He currently serves as a Chaplain with Transport for Christ at ...
(Date:3/1/2017)... ... March 01, 2017 , ... “Letter of Love”: a ... author, Maria Teresa Hamilton, survivor of the Civil War in El Salvador, wife, mother, ... the age of fifteen. I dedicated myself to serve in very poor communities, and ...
Breaking Medicine News(10 mins):